Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Non-cash Items (2016 - 2025)

Tvardi Therapeutics' Non-cash Items history spans 12 years, with the latest figure at $701913.0 for Q4 2025.

  • On a quarterly basis, Non-cash Items fell 75.91% to $701913.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $701913.0, a 75.91% decrease, with the full-year FY2025 number at $701913.0, down 75.91% from a year prior.
  • Non-cash Items hit $701913.0 in Q4 2025 for Tvardi Therapeutics, up from $686194.0 in the prior quarter.
  • Over the last five years, Non-cash Items for TVRD hit a ceiling of $5.1 million in Q1 2023 and a floor of $64989.0 in Q1 2025.
  • Historically, Non-cash Items has averaged $3.3 million across 5 years, with a median of $3.8 million in 2021.
  • Biggest five-year swings in Non-cash Items: soared 59.84% in 2023 and later tumbled 98.65% in 2025.
  • Tracing TVRD's Non-cash Items over 5 years: stood at $4.1 million in 2021, then dropped by 26.52% to $3.0 million in 2022, then skyrocketed by 59.84% to $4.8 million in 2023, then plummeted by 39.79% to $2.9 million in 2024, then plummeted by 75.91% to $701913.0 in 2025.
  • Business Quant data shows Non-cash Items for TVRD at $701913.0 in Q4 2025, $686194.0 in Q3 2025, and $760787.0 in Q2 2025.